Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
83%(5 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
4
50%
Ph phase_2
2
25%
Ph phase_3
2
25%

Phase Distribution

4

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (50.0%)
Phase 22 (25.0%)
Phase 32 (25.0%)

Trials by Status

terminated225%
completed675%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

NCT02136134
completedphase_1

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

NCT00329589
terminatedphase_3

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

NCT00256776
completedphase_1

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
completedphase_2

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

NCT00911859
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02136134Phase 3

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Completed
NCT00329589Phase 1

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

Completed
NCT00256776Phase 3

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Terminated
NCT00469209Phase 1

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Completed
NCT00911859Phase 2

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Completed
NCT00507442Phase 1

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

Completed
NCT00770731Phase 1

Study of Temsirolimus, Topotecan, and Bortezomib

Completed
NCT00106262Phase 2

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8